Live Breaking News & Updates on அண்ணா டன்ஃபி நிக்

Stay updated with breaking news from அண்ணா டன்ஃபி நிக். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |NetScientific PLC Announcements | NetScientific PLC: EMV Capital Advises on £740k Fundraise for Sofant


 
EMV Capital advised on £740k oversubscribed funding round for 5G and satellite phased array designer Sofant Technologies
 
London, UK - 28 April 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability, technology investment and commercialisation group, announces that its corporate finance and venture capital division EMV Capital Ltd ( EMVC ) advised on a £740k oversubscribed top-up fundraise for its Advised Portfolio Company, designer Sofant Technologies ( Sofant ).
 
The fundraise builds on last year s £2.3m pre-series A round for Sofant. Participation in the round included key existing investors, including Kelvin Capital and the Scottish Investment Bank. The funding round included a price per share uplift of 40% in less than one year since its last investment round in July 2020 - reflecting strong developments at Sofant over the period. ....

United States , United Kingdom , City Of , Nicholas Johnson , Anna Dunphy Nick , Darshan Patel , Ilian Iliev , Scottish Investment Bank , London Stock Exchange , European Space Agency , Portfolio Company , Capital Ltd , Advised Portfolio Company , Sofant Technologies , Kelvin Capital , Scottish Investment , European Space , Financial Adviser , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , நிக்கோலஸ் ஜான்சன் , அண்ணா டன்ஃபி நிக் , தரிசனம் படேல் , ஸ்காட்டிஷ் முதலீடு வங்கி , லண்டன் ஸ்டாக் பரிமாற்றம் ,

Investegate |NetScientific PLC Announcements | NetScientific PLC: $60m Commitment for PDS Vaccine Consortium


 
 
c. $60m Funding Commitment by Brazilian government for Clinical Development and Commercialisation of PDS Consortium s COVID-19 Vaccine
 
London, UK - 11 March 2021 - NetScientific plc (AIM: NSCI), the life sciences and sustainability technology investment and commercialisation Group, announces that PDS Biotech s proprietary Versamune®T-cell activating technology, today announced that its COVID-19 vaccine consortium jointly run by PDS consisting of Farmacore Biotechnology and Blanver Farmoquímica, has received a commitment from the Secretary for Research and Scientific Training of the Ministry of Science, Technology and Commercialisation of Brazil ( MCTI ) to fund up to approximately US$60 million to support the clinical development and commercialization of a novel, Versamune®-based, second generation COVID-19 vaccine in Brazil. ....

United States , United Kingdom , City Of , Anna Dunphy Nick , Nicholas Johnson , Helena Faccioli , Darshan Patel , Blanver Farmoqu , Frank Bedu , Ilian Iliev , Scientific Training Of The Ministry Science , Drug Administration , Ministry Of Health , Biotechnology Corporation The Company , United States Securities Exchange , Netscientific Plc , Biotechnology Corporation Nasdaq , Clinical Development , Funding Commitment , Farmacore Biotechnology , Scientific Training , Nacional De Vigil , Frank Bedu Addo , Chief Executive Officer , Latin America , Severe Acute Respiratory Syndrome Coronavirus ,

Investegate |NetScientific PLC Announcements | NetScientific PLC: PDS Phase II Trial Update & Restoration of Trading


 
PDS Biotech Announces Preliminary Efficacy Achievement in Phase II Combination Trial of PDS0101 Led by the National Cancer Institute
 
 
·
The National Cancer Institute s (NCI) Phase II clinical study of PDS Biotech s PDS0101 for HPV-associated cancers has achieved its preliminary objective response.
·
Full enrollment for the Phase II trial is triggered by observation of 3 objective responses in continued evaluation of the initial group of 8 patients
·
Milestone for
treatment of
HPV-associated cancers
 
NetScientific plc (AIM: NSCI), the life sciences, technology, investment and commercialisation company, announces
 
that its portfolio company PDS Biotechnology Corporation ( PDS ) (Nasdaq: PDSB) has achieved its preliminary objective response for the National Cancer Institute s (NCI) Phase II clinical study of PD ....

United States , James Gulley , Anna Dunphy Nick , Darshan Patel , Frank Bedu , Julius Strauss , Jeffrey Schlom , Nicholas Johnson , Stephen Smith , Lauren Wood , Ilian Iliev , Development Agreement , National Cancer Institute , University Of Texas Md Anderson Cancer Center , Cancer Research Laboratory Of Tumor Immunology , Biotechnology Corporation , Biotechnology Corporation Nasdaq , Genitourinary Malignancies Branch , Announces Preliminary Efficacy Achievement , National Cancer , Non Executive Director , Cancer Research , Tumor Immunology , Chief Medical Officer , Cooperative Research , Frank Bedu Addo ,